Connection
Alison Oliveto to Narcotic Antagonists
This is a "connection" page, showing publications Alison Oliveto has written about Narcotic Antagonists.
|
|
Connection Strength |
|
 |
|
 |
|
0.828 |
|
|
|
-
Chopra MP, Feldman Z, Mancino MJ, Oliveto A. Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis. Pharmacol Biochem Behav. 2008 Oct; 90(4):787-96.
Score: 0.288
-
Oliveto A, Benios T, Gonsai K, Feingold A, Poling J, Kosten TR. D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure. Exp Clin Psychopharmacol. 2003 Aug; 11(3):237-46.
Score: 0.201
-
Oliveto A, Sevarino K, McCance-Katz E, Feingold A. Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure. Pharmacol Biochem Behav. 2002 Jan-Feb; 71(1-2):85-96.
Score: 0.181
-
Kosten T, Sofuoglu M, Poling J, Gonsai K, Oliveto A. Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response. Am J Addict. 2005 Jan-Feb; 14(1):8-17.
Score: 0.056
-
Kosten T, Falcioni J, Oliveto A, Feingold A. Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. Am J Addict. 2004 Mar-Apr; 13(2):191-201.
Score: 0.052
-
Gonzalez G, Feingold A, Oliveto A, Gonsai K, Kosten TR. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am J Drug Alcohol Abuse. 2003 Aug; 29(3):497-514.
Score: 0.050